Interestingly, another study using the A2aR antagonist istradefylline in a randomized trial showed that even in patients with the most advanced PD, it reduced the time spent in the dyskinesia 'off' state, though it did not reduce severity when the symptoms set in [56]. This evidence concerns the gene ADORA2A and Parkinson disease.